收藏切换
Study on the anticoagulation effects of nafamostat mesylate in maintenance hemodialysis
收藏切换
Zhixiang BIAN, Xiaoxuan SU, Xiangxiang WANG, Zhongsu ZHU, Rui ZHU*, Shunjie CHEN*
World Clinical Drug | 2023, 44(6) : 599 - 603
Less
收藏切换
World Clinical Drug | 2023, 44(6): 599-603
• Article •
Study on the anticoagulation effects of nafamostat mesylate in maintenance hemodialysis
Full
Zhixiang BIAN, Xiaoxuan SU, Xiangxiang WANG, Zhongsu ZHU, Rui ZHU*, Shunjie CHEN*
Affiliations
  • Department of Nephrology, Shanghai Fourth People's Hospital, Shanghai 200434, China
Published: 2023-06-10 doi: 10.13683/j.wph.2023.06.014
Outline
收藏切换
Objective

To evaluate the efficacy and safety of nafamostat mesylate as an anticoagulant regimen in maintenance hemodialysis (MHD).

Methods

30 patients with high risk of bleeding in the department of nephrology, Shanghai fourth people's hospital were selected as the observation group, receiving the anticoagulant regimen of nafamostat mesylate, and 30 patients with MHD were selected as the control group, receiving the anticoagulant regimen of ordinary heparin. Blood routine, liver and kidney function, blood lipid status, compression hemostasis time of arterial puncture point, and activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) in vitro and in vivo were observed before and after MHD in the two groups.

Results

The levels of blood urea and creatinine after MHD in both groups were significantly lower than those before dialysis (P<0.05). In the observation group, APTT index in vivo was not significantly prolonged after HD, but APTT index in vitro was significantly prolonged (P<0.05). In the control group, APTT and TT index in vivo and in vitro were significantly prolonged (P<0.05). In terms of mechanical coagulation observation, the compression hemostasis time of MHD artery puncture in the observation group was significantly shorter than that in the control group (P<0.05).

Conclusion

Nafamostat mesylate is a safe and effective anticoagulant regimen for MHD patients at high risk of bleeding.

nafamostat mesylate  /  hemodialysis  /  high risk of bleeding  /  coagulation function
卞志翔, 苏晓璇, 汪想想, 朱中苏, 朱蕊, 陈舜杰. 甲磺酸萘莫司他抗凝在维持性血液透析中的效果研究. 世界临床药物, 2023 , 44 (6) : 599 -603 . DOI: 10.13683/j.wph.2023.06.014
Zhixiang BIAN, Xiaoxuan SU, Xiangxiang WANG, Zhongsu ZHU, Rui ZHU, Shunjie CHEN. Study on the anticoagulation effects of nafamostat mesylate in maintenance hemodialysis[J]. World Clinical Drug, 2023 , 44 (6) : 599 -603 . DOI: 10.13683/j.wph.2023.06.014
Year 2023 volume 44 Issue 6
17
2
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2023.06.014
  • Receive Date:2022-04-15
  • Online Date:2026-11-18
  • Published:2023-06-10
Article Data
Affiliations
History
  • Received:2022-04-15
  • Revised:2023-01-12
Funding
Affiliations
    Department of Nephrology, Shanghai Fourth People's Hospital, Shanghai 200434, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.06.014
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT